Global Asthma & COPD Therapies Market 2019-2029
The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 309-page report you will receive 112 tables and 131 figures– all unavailable elsewhere.
The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:
- Global Asthma Therapies Market forecasts
- Global COPD Therapies Market forecasts
- Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
- Bronchodilators monotherapy
- Anti-inflammatory drugs
- Combination drugs
- Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
- Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
- Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
- Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris
- Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
- Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
- Anti-leukotrienes: Singulair
- Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
- Revenue forecast for the Combination drugs market and the leading drugs:
- Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo
- This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:
- The US
- Japan
- EU5: Germany, France, UK, Italy, Spain
- BRIC: Brazil, Russia, India, China
- Mexico
- Other Countries
- This report discusses the leading companies in the global asthma & COPD therapies market:
- AstraZeneca
- Boehringer Ingelheim
- GSK
- Merck
- Novartis
- Roche
- Teva
- This report discusses drugs currently in clinical development for treating asthma and COPD.
- This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Global Asthma and COPD Therapies Market Overview
- 1.2 Global Asthma and COPD Therapies Market Segmentation
- 1.3 Why You Should Read This Report
- 1.4 How This Report Delivers
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.8 Frequently Asked Questions (FAQ)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2. Introduction to Asthma and COPD Therapies
- 2.1 The Pharmaceutical Industry: A Very Brief Overview
- 2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
- 2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
- 2.3 What is Asthma?
- 2.3.1 Trends in Asthma Prevalence
- 2.3.2 Pathophysiology of Asthma
- 2.3.3 Symptoms of Asthma
- 2.3.4 Causes and Triggers for Asthma
- 2.3.5 Treatment of Asthma
- 2.3.6 Guidelines for Asthma Treatment
- 2.3.7 Drug Treatments for Asthma
- 2.3.8 Drug Delivery Methods in Asthma
- 2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
- 2.4.1 Trends in COPD Prevalence
- 2.4.2 Pathophysiology of COPD
- 2.4.3 Signs and Symptoms of COPD
- 2.4.4 Treatment of COPD
- 2.4.5 Drug Treatments for COPD
- 2.4.6 Guidelines for COPD Treatment
- 2.5 Major Drug Classes in the Treatment of Asthma and COPD
- 2.5.1 Bronchodilators
- 2.5.1.1 Beta2-Agonists
- 2.5.1.2 Anticholinergics
- 2.5.2 Anti-Inflammatory Drugs
- 2.5.2.1 Corticosteroids
- 2.5.2.2 Leukotriene Receptor Antagonists
- 2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
- 2.5.3 Combination Drugs
- 2.6 Phases of Clinical Trials
- 2.7 Scope of this Report
- 3. Asthma and COPD Therapies: Global Market 2019-2029
- 3.1 The Global Respiratory Drugs Market by Therapeutic Area
- 3.2 The Global Asthma and COPD Therapies Market in 2018
- 3.2.1 Leading Asthma and COPD Therapies
- 3.2.2 Leading Companies in the Asthma and COPD Therapies Market
- 3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2017-2029
- 3.3.1 Global Asthma Therapies Market: Sales Forecast, 2017-2029
- 3.3.2 Global COPD Therapies Market: Sales Forecast 2017-2029
- 3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2017-2029
- 3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
- 3.6 How Will Segmental Shares Change to 2029
- 3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2017-2029
- 3.7 Asthma and COPD Therapies: Trends and Developments
- 3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
- 3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
- 4. Bronchodilator Monotherapy Market 2019-2029
- 4.1 Introduction to Bronchodilator Monotherapy
- 4.2 The Bronchodilator Monotherapy Market in 2017
- 4.2.1 Leading Bronchodilators in 2017
- 4.2.2 Bronchodilator Monotherapy: Market Forecast 2019-2029
- 4.2.3 How Will Market Shares by Drug Class Change to 2029?
- 4.3 The Anticholinergics Market 2019-2029
- 4.3.1 Leading Anticholinergics in 2017
- 4.3.2 Anticholinergics: Market Forecast 2019-2029
- 4.3.3 Market Share of Leading Anticholinergics to 2029
- 4.3.4 Spiriva (tiotropium - Boehringer Ingelheim)
- 4.3.4.1 Spiriva: Sales Forecast 2019-2029
- 4.3.4.2 Spiriva: Recent Developments
- 4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
- 4.3.5.1 Atrovent: Sales Forecast 2019-2029
- 4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
- 4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2017-2029
- 4.4 The SABAs Market 2019-2029
- 4.4.1 Leading SABAs in 2017
- 4.4.2 SABAs: Market Forecast 2019-2029
- 4.4.3 Market Share of Leading SABAs to 2029
- 4.4.4 Ventolin (salbutamol, GSK)
- 4.4.4.1 Ventolin: Sales Forecast 2019-2029
- 4.4.5 ProAir (salbutamol, Teva)
- 4.4.5.1 ProAir: Sales Forecast 2019-2029
- 4.4.6 Proventil (salbutamol, Merck)
- 4.4.6.1 Proventil: Sales Forecast 2019-2029
- 4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
- 4.4.7.1 Xopenex: Sales Forecast 2019-2029
- 4.5 The Long-Acting Beta2-Agonist (LABA) Market 2017-2029
- 4.5.1 Leading LABAs in 2017
- 4.5.2 LABAs: Market Forecast 2019-2029
- 4.5.3 Market Share of Leading LABAs to 2029
- 4.5.4 Foradil (formoterol, Merck/Novartis)
- 4.5.4.1 Foradil: Sales Forecast 2017-2029
- 4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
- 4.5.5.1 Brovana: Sales Forecast 2017-2029
- 4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
- 4.5.6.1 Arcapta/Onbrez: Sales Forecast 2017-2029
- 4.5.7 Serevent (salmeterol, GSK)
- 4.5.7.1 Serevent: Sales Forecast 2017-2029
- 5. Anti-inflammatory Drugs Market 2019-2029
- 5.1 Introduction to Anti-Inflammatory Drugs
- 5.2 The Anti-Inflammatory Drugs Market in 2017
- 5.2.1 Leading Anti-Inflammatory Drugs in 2017
- 5.2.2 Anti-Inflammatory Drugs: Market Forecast 2019-2029
- 5.2.3 How Will Market Shares by Drug Class Change to 2029?
- 5.3 The Corticosteroids Market 2019-2029
- 5.3.1 Leading Corticosteroids in 2017
- 5.3.2 Corticosteroids: Market Forecast 2019-2029
- 5.3.3 Market Share of Leading Corticosteroids to 2029
- 5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
- 5.3.4.1 Flixotide/Flovent: Sales Forecast 2019-2029
- 5.3.5 Pulmicort (budesonide, AstraZeneca)
- 5.3.5.1 Pulmicort: Sales Forecast 2019-2029
- 5.3.6 QVAR (beclometasone, Teva)
- 5.3.6.1 QVAR: Sales Forecast 2017-2029
- 5.3.7 Asmanex (mometasone, Merck)
- 5.3.7.1 Asmanex: Sales Forecast 2019-2029
- 5.4 The Anti-Leukotrienes Market 2019-2029
- 5.4.1 Leading Anti-Leukotrienes in 2017
- 5.4.2 Anti-Leukotrienes: Market Forecast 2019-2029
- 5.4.3 Market Share of Leading Anti-Leukotrienes to 2029
- 5.4.4 Singulair (montelukast, Merck)
- 5.4.4.1 Singulair: Sales Forecast 2017-2029
- 5.5 The Monoclonal Antibodies Market 2019-2029
- 5.5.1 Monoclonal Antibodies: Market Forecast 2019-2029
- 5.5.2 Market Share of Leading Monoclonal Antibodies to 2029
- 5.5.3 Xolair (omalizumab, Novartis/Roche)
- 5.5.3.1 Xolair: Sales Forecast 2019-2029
- 5.5.4 Cinquil/Cinquair (reslizumab, Teva)
- 5.5.4.1 Cinquil: Sales Forecast 2019-2029
- 5.5.5 Nucala (Mepolizumab, GSK)
- 5.5.5.1 Nucala: Sales Forecast 2019-2029
- 5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
- 5.5.6.1 Benralizumab: Sales Forecast 2019-2029
- 5.5.7 Lebrikizumab (RG3637, Roche)
- 5.5.7.1 Lebrikizumab: Sales Forecast 2019-2029
- 5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
- 5.5.8.1 Dupilumab: Sales Forecast 2017-2029
- 6. Combination Drugs Market 2019-2029
- 6.1 Introduction to Combination Drugs
- 6.1.1 Leading Combination Drugs in 2017
- 6.1.2 Combination Drugs: Market Forecast 2017-2029
- 6.1.3 How Will Market Shares by Drug Change to 2029?
- 6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
- 6.1.4.1 Advair/Seretide: Sales Forecast 2017-2029
- 6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
- 6.1.5.1 Symbicort: Sales Forecast 2017-2029
- 6.1.5.2 Symbicort: The SMART Concept
- 6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
- 6.1.6.1 Combivent: Sales Forecast 2017-2029
- 6.1.7 Dulera (formoterol/mometasone, Merck)
- 6.1.7.1 Dulera: Sales Forecast 2017-2029
- 6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
- 6.1.8.1 Breo/Relvar: Sales Forecast 2017-2029
- 6.2 Recently Launched Combination Drugs
- 7. Leading National Markets 2017-2029
- 7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
- 7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2017-2029
- 7.2.1 How Will Regional Market Shares Change to 2029?
- 7.2.2 National Breakdown of the Global Asthma and COPD Therapies Market
- 7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2017-2029
- 7.2.4 How Will National Market Shares Change to 2029?
- 7.3 The US Asthma and COPD Therapies Market 2017-2029
- 7.3.1 The US Asthma and COPD Therapies Market Forecast 2017-2029
- 7.3.2 US Asthma and COPD Therapies Market Trends and Developments
- 7.3.2.1 Increasing COPD Prevalence in the US
- 7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
- 7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
- 7.4 Japanese Asthma and COPD Therapies Market 2017-2029
- 7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2017-2029
- 7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
- 7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
- 7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
- 7.5 EU5 Asthma and COPD Therapies Market 2017-2029
- 7.5.1 German Asthma and COPD Therapies Market Forecast 2017-2029
- 7.5.2 French Asthma and COPD Therapies Market Forecast 2017-2029
- 7.5.3 UK Asthma and COPD Therapies Market Forecast 2017-2029
- 7.5.4 Italian Asthma and COPD Therapies Market Forecast 2017-2029
- 7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2017-2029
- 7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
- 7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
- 7.5.6.2 France: Social Security Finance Bill 2015
- 7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
- 7.5.6.4 Italy: Austerity Measures Limiting Growth
- 7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
- 7.6 BRIC Asthma and COPD Therapies Market 2017-2029
- 7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2017-2029
- 7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
- 7.6.2.1 China’s Industrial Future and Asthma/COPD
- 7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
- 7.6.2.3 Price Controls and the Anhui Model
- 7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2017-2029
- 7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
- 7.6.4.1 Increasing Access to Medicines
- 7.6.5 Indian Asthma and COPD Therapies Market Forecast 2017-2029
- 7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
- 7.6.6.1 Drug Prices Control Order 2013
- 7.6.6.2 Expansion of Healthcare Provision
- 7.6.7 Russian Asthma and COPD Therapies Market Forecast 2017-2029
- 7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
- 7.6.8.1 No Embargo on Foreign Drug Imports
- 7.6.8.2 Pharma2021 and the Russian Pharmaceutical Industry
- 7.7 Mexican Asthma and COPD Therapies Market 2017-2029
- 7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2017-2029
- 7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
- 7.7.2.1 Seguro Popular: Mexican Healthcare Reform
- 7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
- 7.7.2.3 Mexico’s Agreement for Innovation
- 8. Leading Companies in the Asthma and COPD Therapies Market
- 8.1 Asthma and COPD Therapies: Increasing Competition
- 8.2 Leading Companies in Asthma and COPD in 2017
- 8.3 Leading Companies: Market Forecast 2017-2029
- 8.4 How Will Leading Companies’ Market Shares Change to 2029?
- 8.5 GSK
- 8.5.1 GSK: Asthma and COPD Therapies
- 8.5.2 GSK: Sales Forecast 2017-2029
- 8.5.3 GSK: Products in Development
- 8.5.4 GSK: Recent Developments
- 8.5.4.1 Recently Launched Combination Drugs
- 8.5.4.2 GSK Divests OTC Products
- 8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
- 8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
- 8.6 Boehringer Ingelheim
- 8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
- 8.6.2 Boehringer Ingelheim: Sales Forecast 2017-2029
- 8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
- 8.6.4 Boehringer Ingelheim: Recent Developments
- 8.6.4.1 Expansion of Respimat Manufacturing Capacity
- 8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
- 8.6.4.3 Ben Venue Laboratories Shut Down
- 8.6.4.4 Sale of Roxane Laboratories
- 8.6.4.5 Spiloto Respimat and the PHYSACTO Study
- 8.7 AstraZeneca
- 8.7.1 AstraZeneca: Asthma and COPD Therapies
- 8.7.2 AstraZeneca: Sales Forecast 2017-2029
- 8.7.3 AstraZeneca: Products in Development
- 8.7.4 AstraZeneca: Recent Developments
- 8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
- 8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
- 8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
- 8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
- 8.7.4.5 Takeda Respiratory Portfolio Acquisition
- 8.8 Merck & Co. (Merck)
- 8.8.1 Merck: Asthma and COPD Therapies
- 8.8.2 Merck: Sales Forecast 2017-2029
- 8.8.3 Merck: Products in Development
- 8.8.4 Merck: Recent Developments
- 8.8.4.1 Bayer Acquires Merck’s Consumer Health Business
- 8.8.4.2 FDA Rejects Singulair OTC Switch
- 8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
- 8.9 Novartis
- 8.9.1 Novartis: Asthma and COPD Therapies
- 8.9.2 Novartis: Sales Forecast 2017-2029
- 8.9.3 Novartis: Products in Development
- 8.9.4 Novartis: Recent Developments
- 8.9.4.1 Novartis Restructures Following Strategic Review
- 8.9.4.2 Novartis Presents Data on Ultibro and Seebri
- 8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
- 8.10 Roche
- 8.10.1 Roche: Asthma and COPD Therapies
- 8.10.2 Roche: Sales Forecast 2017-2029
- 8.10.3 Roche: Products in Development
- 8.11 Teva
- 8.11.1 Teva: Asthma and COPD Therapies
- 8.11.2 Teva: Sales Forecast 2017-2029
- 8.11.3 Teva: Products in Development
- 8.11.4 Teva: Recent Developments
- 8.11.4.1 Launch of DuoResp Spiromax
- 9. Asthma and COPD Therapies Pipeline Analysis 2017-2029
- 9.1 A Strong Asthma and COPD Pipeline
- 9.2 The Bronchodilators Pipeline
- 9.2.1 Bronchodilators: Phase 3 Pipeline
- 9.2.1.1 AZD8871 (MABA, AstraZeneca)
- 9.2.1.2 GSK961081 (Batefenterol, GSK)
- 9.2.1.3 LAS100977 (Abediterol, AstraZeneca)
- 9.2.1.4 QVAR BAI (beclometasone, Teva)
- 9.3 The Anti-Inflammatory Drugs Pipeline
- 9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
- 9.3.1.1 mepolizumab (IL-5 receptor antagonist, GSK)
- 9.3.1.2 benralizumab (IL-5 receptor antagonist, AstraZeneca)
- 9.3.1.3 tralokinumab (IL-13 receptor antagonist, AstraZeneca)
- 9.3.1.4 QAW039 (fevipiprant, Novartis)
- 9.3.1.5 Lebrikizumab (IL-13 receptor antagonist, Roche)
- 9.4 The Combination Drugs Pipeline
- 9.4.1 Combination Drugs: Phase 3 Pipeline
- 9.4.1.1 fluticasone furoate & vilanterol & umeclidinium (GSK)
- 9.4.1.2 PT010 (long-acting muscarinic antagonist (LAMA) glycopyrronium, the long acting β2-agonist (LABA) formoterol fumarate and budesonide, an inhaled corticosteroid (ICS), AstraZeneca)
- 9.4.1.3 QMF149 (indacaterol, mometasone furoate, Novartis)
- 9.4.1.4 QVM149 (indacaterol, glycopyrronium, mometasone, Novartis)
- 9.5 Other Asthma and COPD Drugs Pipeline
- 10. Qualitative Analysis of the Asthma and COPD Therapies Market 2017-2029
- 10.1 SWOT Analysis of the Asthma and COPD Therapies Market
- 10.2 Strengths
- 10.2.1 Increasing Prevalence and Disease Burden
- 10.2.2 High Costs of Treatment
- 10.2.3 The Changing Perception of COPD
- 10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
- 10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
- 10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
- 10.2.7 Developments in Diagnostics
- 10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
- 10.2.7.2 Biological Markers in COPD
- 10.3 Weaknesses
- 10.3.1 Under-Diagnosis: the ‘Ghost Population’
- 10.3.2 Side-Effects of Drug Classes
- 10.3.3 Patent Cliff for Devices
- 10.3.4 Low Patient Adherence
- 10.3.5 Costing Pressures in both Developed and Emerging Markets
- 10.4 Opportunities
- 10.4.1 Patient Phenotyping and Personalised Medicine
- 10.4.2 A Strong R&D Pipeline
- 10.4.3 Ultra-Long-Acting Beta2-Agonists
- 10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
- 10.4.5 Monoclonal Antibodies
- 10.4.6 LAMA/LABA Combinations
- 10.4.7 Opportunities in Telehealth
- 10.5 Threats
- 10.5.1 Patent Expiry and Generic Competition
- 10.5.2 Pharmacy Benefit Managers and Cost Control
- 10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
- 10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
- 10.6.1 Rivalry among Competitors [Medium]
- 10.6.2 Threat of New Entrants [Medium]
- 10.6.3 Power of Suppliers [Medium]
- 10.6.4 Power of Buyers [High]
- 10.6.5 Threat of Substitutes [Low]
- 11. Conclusions
- 11.1 Asthma and COPD Therapies: A Maturing Market
- 11.2 The Global Asthma and COPD Therapies Market in 2017
- 11.3 Current Leading Asthma and COPD Therapies Segments
- 11.3.1 Leading Asthma and COPD Therapies
- 11.3.2 Leading Asthma and COPD Therapies Companies
- 11.4 Leading Regional and National Markets
- 11.5 Global Asthma and COPD Therapies Market Forecast 2017-2029
- 11.6 The Future of the Asthma and COPD Therapies Market
- 11.6.1 Growth in Anti-Inflammatory and Combination Drugs
- 11.6.2 Personalised Medicine
- 11.6.3 Unmet Needs in Asthma and COPD
- 11.7 Strategies for Growth in 2017-2029
- Appendices
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- Appendix A
- About Visiongain
- Appendix B
- Visiongain report evaluation form
- List of Tables
- Table 2.1 Classification of Respiratory Diseases, 2018
- Table 2.2 Causes of Asthma, 2018
- Table 2.3 Triggers of Asthma, 2018
- Table 2.4 Clinical Trial Phases
- Table 3.1 Global Asthma & COPD Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2018
- Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2017
- Table 3.3 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
- Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2018, 2023 and 2029
- Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018
- Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2017
- Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
- Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2017
- Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018, 2023 and 2029
- Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.10 Leading SABAs in 2017
- Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 4.12 SABAs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
- Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2017
- Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2017, 2023 and 2029
- Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2017
- Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2017
- Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
- Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2023 and 2029
- Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2017
- Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2017, 2023 and 2029
- Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
- Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2017
- Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2017, 2023 and 2029
- Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017, 2023 and 2029
- Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2017
- Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
- Table 6.4 GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2017
- Table 7.2 Global Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2017-2029
- Table 7.3 Leading Regional Asthma and COPD Therapies Market: Market Share (%) 2018, 2023 and 2029
- Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2018
- Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
- Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2018, 2023 and 2029
- Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
- Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
- Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
- Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
- Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2017
- Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
- Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2017, 2023 and 2029
- Table 8.4 GSK: Overview
- Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
- Table 8.7 GSK: Asthma and COPD Therapies Pipeline
- Table 8.8 Boehringer Ingelheim: Overview
- Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 8.11 AstraZeneca: Overview
- Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
- Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline
- Table 8.15 Merck: Overview
- Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
- Table 8.18 Novartis: Overview
- Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
- Table 8.21 Novartis: Asthma and COPD Therapies Pipeline
- Table 8.22 Roche: Overview
- Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
- Table 8.24 Teva: Overview
- Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
- Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
- Table 8.27 Teva: Asthma and COPD Therapies Pipeline
- List of Figures
- Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2018
- Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2018
- Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2018
- Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2018
- Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2018
- Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2017
- Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2018
- Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2023
- Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2029
- Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2017-2029
- Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2018
- Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2023
- Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2029
- Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018
- Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2023
- Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2029
- Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2017-2029
- Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2017-2029
- Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2017-2029
- Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2018
- Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2023
- Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2029
- Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2017-2029
- Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2017-2029
- Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2017-2029
- Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2017-2029
- Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2018
- Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2023
- Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2029
- Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2017-2029
- Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2017-2029
- Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2017-2029
- Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2017-2029
- Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2017
- Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2017
- Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2023
- Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2023
- Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2029
- Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2029
- Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2017
- Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2023
- Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2029
- Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
- Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2017-2029
- Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2017-2029
- Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2017-2029
- Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2018
- Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2023
- Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2029
- Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2017-2029
- Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017
- Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2023
- Figure 5.24 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2029
- Figure 5.25 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2017-2029
- Figure 5.26 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2017-2029
- Figure 5.27 GSK: Nucala Revenue ($m) and AGR (%), 2017-2029
- Figure 5.28 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2017-2029
- Figure 5.29 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2017-2029
- Figure 5.30 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2017-2029
- Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
- Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2017
- Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2023
- Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2029
- Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2017-2029
- Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2017-2029
- Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2017-2029
- Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2017-2029
- Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2017-2029
- Figure 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) by Region, 2017
- Figure 7.2 Global Asthma and COPD Therapies Market: Market Shares (%) by Region, 2017
- Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2017-2029
- Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2023
- Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2029
- Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2018
- Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2018
- Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2023
- Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2029
- Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
- Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2017-2029
- Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
- Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
- Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
- Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2017
- Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2017
- Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2023
- Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2023
- Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2029
- Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2029
- Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
- Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
- Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
- Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2017-2029
- Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2017-20279
- Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2017-2029
- Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2017-2029
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
